Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Clémentine Estric, Thomas Duron, Sarah Kabani, Jorge Lopez-Castroman
Journal of Psychopharmacology May 12, 2025 DOI: 10.1177/02698811251338214 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Open-label Peer reviewed |
|---|---|
| Sample size | 763 |
| Population | Participants in clinical trials of psychedelics for psychiatric disorders |
| Topics | Ayahuasca DMT LSD Psilocybin Psychedelic-assisted therapy |
| Keywords | Context Pap Therapeutic procedures Medical standards Therapeutic space Environment Treatment conditions |
| Citations | 10 |
| Key findings | Participant selection and safe environment creation were consistently reported across psychedelic clinical trials, but other aspects of set and setting like monitor training, visual distractors, and pleasant environment were not standardized, limiting comparability and reproducibility. |
Abstract
Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases until 12 December 2023. Only clinical trials published in English or French were eligible, and studies using psychedelics for withdrawal were excluded. Sixteen domains of set and setting were assessed covering participant selection, pre- and post-session interventions, monitor presence, environmental management, and end-of-session procedure. Of 4912 articles screened, 27 articles were retained reporting on 25 studies. Thirteen of the included studies reported randomized trials, while 12 were open-label studies, on a total of 763 participants. Studies considered features of set and setting to different extents. Participant selection and the creation of a safe environment were consistently present, but articles were more heterogeneous about reporting monitor training (52%), controlling visual distractors (64%) and creating a pleasant environment (68%). Psilocybin was over-represented (47%). Many key elements were described in each study, but differences in set and setting limit comparability and reproducibility. Harmonizing these aspects would aid the interpretation of future studies and help understand the effect of psychedelics in psychiatry.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Participant selection and safe environment creation were consistently reported, but other set-and-setting elements such as monitor training, visual distractors, and pleasant environment were not standardized, limiting comparability.
Synthesized
Comparable studies
Other systematic reviews and meta-analyses on LSD and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Participants in studies of psychedelic therapy for depressive symptoms (Major... | 2023 | Systematic review with meta-analysis | n = 14 |
| United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. | 2022 | Systematic review | |
| Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review. Human subjects in studies of psychedelic-assisted psychotherapy | 2024 | Systematic review and meta-analysis | n = 30 |
| The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. Patients with alcohol use disorder | 2024 | Systematic review and meta-analysis |
Citations in the library
Cited by 16
- Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives. General Hospital Psychiatry July 3, 2025
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry. Journal of Personalized Medicine September 28, 2025
- Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols. European Neuropsychopharmacology January 16, 2026
- From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care Translational Behavioral Medicine 2026
- Systems-based psychiatry: insights from psychedelic research on mechanisms of healing Frontiers in Psychiatry July 13, 2026
and 11 more in the library
Cites 64
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 59 more in the library